Skip to content
Open access

Calycosin-7-O-β-D-glucoside alleviates neurological injury after traumatic brain injury: involvement of cGAS-STING signaling and mitochondrial dynamics.

Oct 2026 · European Journal of Pharmacology · pp. 179495 · 0 citations · 50 references
Medicine

Abstract

Secondary neurological injury is a major determinant of functional outcome after traumatic brain injury (TBI) and is closely linked to mitochondrial dysfunction and disrupted mitochondrial dynamics. Calycosin-7-O-β-D-glucoside (CAG) has antioxidant and mitochondria-protective properties, but its therapeutic potential in TBI remains unclear. The present study demonstrated that CAG significantly improved neurological, behavioral, and cognitive outcomes in mice with controlled cortical impact (CCI)-induced TBI, while alleviating histopathological damage, neuronal apoptosis, glial activation, and mitochondrial ultrastructural abnormalities. Consistently, in H2O2-treated HT22 cells, CAG reduced oxidative stress, mitochondrial dysfunction, and apoptosis. Mechanistically, transcriptomic, protein, and confocal immunofluorescence analyses showed that CAG reduced aberrant cGAS-STING signaling and attenuated abnormal subcellular redistribution of activated STING. In parallel, CAG restored mitochondrial dynamics, with a reduced p-DRP1 (Ser616)/DRP1 ratio and increased MFN1, MFN2, and OPA1 expression. Notably, DMXAA partially reversed CAG-mediated restoration of mitochondrial dynamics and neuroprotection, suggesting the involvement of STING signaling. CAG promotes neurological recovery after TBI by restoring mitochondrial dynamics homeostasis and attenuating neuronal injury, with the findings supporting the involvement of reduced cGAS-STING signaling in these effects. This study provides experimental evidence supporting CAG as a potential pharmacological strategy for mitigating secondary injury after TBI.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.